More frequent meetings with FDA to discuss the drug's development plan and ensure collection of appropriate data needed to support drug approval Improving the diagnosis of a serious condition where early diagnosis results in an improved outcomeĭecreasing a clinical significant toxicity of an available therapy that is common and causes discontinuation of treatmentĪbility to address emerging or anticipated public health needĪ drug that receives Fast Track designation is eligible for some or all of the following:

Showing superior effectiveness, effect on serious outcomes or improved effect on serious outcomesĪvoiding serious side effects of an available therapy.If there are available therapies, a fast track drug must show some advantage over available therapy, such as: However, diseases such as epilepsy, depression and diabetes are also considered to be serious conditions.įilling an unmet medical need is defined as providing a therapy where none exists or providing a therapy which may be potentially better than available therapy.Īny drug being developed to treat or prevent a condition with no current therapy obviously is directed at an unmet need. AIDS, Alzheimer’s, heart failure and cancer are obvious examples of serious conditions. Fast Track addresses a broad range of serious conditions.ĭetermining whether a condition is serious is a matter of judgment, but generally is based on whether the drug will have an impact on such factors as survival, day-to-day functioning, or the likelihood that the condition, if left untreated, will progress from a less severe condition to a more serious one. The purpose is to get important new drugs to the patient earlier. Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

Fasttrack schedule 2017